Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18,045 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
Kalogera E, Nevala WK, Finnes HD, Suman VJ, Schimke JM, Strand CA, Kottschade LA, Kudgus RA, Buhrow SA, Becher LR, Geng L, Glaser GE, Grudem ME, Jatoi A, Klampe CM, Kumar A, Langstraat CL, McWilliams RR, Wahner Hendrickson AE, Weroha SJ, Yan Y, Reid JM, Markovic SN, Block MS. Kalogera E, et al. Among authors: yan y. Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3196. Online ahead of print. Clin Cancer Res. 2024. PMID: 38530846
Resolving the heterogeneous tumor-centric cellular neighborhood through multiplexed, spatial paracrine interactions in the setting of immune checkpoint blockade.
Maus RLG, Leontovich AL, Moore RM, Becher L, Nevala WK, Flotte TJ, Guo R, Schimke J, Dicke BA, Yan Y, Markovic SN. Maus RLG, et al. Among authors: yan y. Cancer Res Commun. 2022 Feb;2(2):78-89. doi: 10.1158/2767-9764.crc-21-0146. Epub 2022 Feb 10. Cancer Res Commun. 2022. PMID: 35992329 Free PMC article.
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Smith KER, Peng KW, Pulido JS, Weisbrod AJ, Strand CA, Allred JB, Newsom AN, Zhang L, Packiriswamy N, Kottke T, Tonne JM, Moore M, Montane HN, Kottschade LA, McWilliams RR, Dudek AZ, Yan Y, Dimou A, Markovic SN, Federspiel MJ, Vile RG, Dronca RS, Block MS. Smith KER, et al. Among authors: yan y. Front Immunol. 2023 Oct 31;14:1279387. doi: 10.3389/fimmu.2023.1279387. eCollection 2023. Front Immunol. 2023. PMID: 38022659 Free PMC article. Clinical Trial.
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Hieken TJ, et al. Among authors: yan y. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8. Nat Commun. 2024. PMID: 38365756 Free PMC article. Clinical Trial.
Neoadjuvant systemic therapy for regionally advanced melanoma.
Jakub JW, Racz JM, Hieken TJ, Gonzalez AB, Kottschade LA, Markovic SN, Yan Y, Block MS. Jakub JW, et al. Among authors: yan y. J Surg Oncol. 2018 May;117(6):1164-1169. doi: 10.1002/jso.24939. Epub 2017 Dec 11. J Surg Oncol. 2018. PMID: 29228467
Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy.
Saliba AN, Xie Z, Higgins AS, Andrade-Gonzalez XA, Fuentes-Bayne HE, Hampel PJ, Kankeu Fonkoua LA, Childs DS, Rakshit S, Bezerra ED, Kommalapati A, Lou Y, Rivera CE, Price KA, Chintakuntlawar A, Yan Y, Schwecke AJ, Block MS, Thanarajasingam U, Thanarajasingam G, Wolanskyj-Spinner AP, Marshall AL, Kottschade LA, Go RS, Al-Kali A. Saliba AN, et al. Among authors: yan y. Am J Hematol. 2021 Oct 1;96(10):E362-E367. doi: 10.1002/ajh.26273. Epub 2021 Jul 2. Am J Hematol. 2021. PMID: 34137072 Free article. No abstract available.
18,045 results
You have reached the last available page of results. Please see the User Guide for more information.